Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the role of glucagon action in the metabolic phenotype of untreated insulin deficiency. RESEARCH DESIGN AND METHODS: We compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr−/−) mice and wild-type (Gcgr+/+) controls after equivalent destruction of β-cells. We used a double dose of streptozotocin to maximize β-cell destruction. RESULTS: Gcgr+/+ mice became hyperglycemic (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks. Despite comparable β-cell destruction in Gcgr−/− mice, none of the foregoing clinical or laboratory manifestations of diabetes appeared. There was marked α-cell hyperplasia and hyperglucagonemia (∼1,200 pg/mL), but hepatic phosphorylated cAMP response element binding protein and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced compared with Gcgr+/+ mice with diabetes—evidence that glucagon action had been effectively blocked. Fasting glucose levels and oral and intraperitoneal glucose tolerance tests were normal. Both fasting and nonfasting free fatty acid levels and nonfasting β-hydroxy butyrate levels were lower. CONCLUSIONS: We conclude that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While lack of GCGR signaling can normalize glycemia under insulin-deficient conditions15,16, this effect is contingent on the presence of residual insulin17.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563 · cited 5×
“Male mice with global glucagon receptor knockout and wild-type mice (19)”
BackgroundSelf-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundTHE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*
Unger, R. H., Eisentraut, A. M., & Madison, L. L. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104788 · Cited by 345 · cited 1×
“Glucagon was immunocytochemically localized to pancreatic a-cells (3) and shown to be secreted in response to increased glucose need, as in starvation and exercise (4).”
BackgroundSelf-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327 · cited 6×
“The search for more practical suppressors or antagonists of glucagon has been reenergized by the recent demonstration that leptin can suppress diabetic hyperglucagonemia and reverse the catabolic effects of complete insulin deficiency for extended periods without apparent negative consequences (11,12).”
BackgroundResultSelf-citationCREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ
Herzig, S., Hedrick, S., Morantte, I., Koo, S.-H., Galimi, F., & Montminy, M. (2003) · Nature · doi:10.1038/nature02110 · Cited by 321 · cited 2×
“Uncontrolled insulin deficiency with hyperglucagonemia is characterized by increased gluconeogenesis associated with upregulation of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) (29,30).”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast to normal a-cells, which are restrained by the high local concentrations of intraislet insulin (22), type 1 diabetic a-cells are unregulated, which results in inappropriate hyperglucagonemia (5).”
BackgroundSelf-citationAntidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 2×
“More recently, the same antidiabetic efficacy has been demonstrated with recombinant leptin (11,23).”
BackgroundUnger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104525 · Cited by 278 · cited 1×
“The development of a radioimmunoassay for glucagon (1) established the hormonal status of this peptide (2), originally considered to be a contaminant of the insulin extraction process.”
BackgroundSelf-citation
Cited by
Items 201–300 of 326
Li, X. C., & Zhuo, J. L. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0383-y · Cited by 17
Coffee Ingestion Suppresses Hyperglycemia in Streptozotocin-Induced Diabetic Mice
Kobayashi, M., KURATA, T., HAMANA, Y., Hiramitsu, M., Inoue, T., Murai, A., & Horio, F. (2017) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.63.200 · Cited by 17
Importance of multiple endocrine cell types in islet organoids for type 1 diabetes treatment
Heaton, E. S., & Jin, S. (2022) · Translational research · doi:10.1016/j.trsl.2022.06.014 · Cited by 16
Filippello, A., Scamporrino, A., Mauro, S. D., Malaguarnera, R., Pino, A. D., Scicali, R., Purrello, F., & Piro, S. (2020) · Biomolecules · doi:10.3390/biom10101404 · Cited by 15
Irwin, N., Pathak, V., Pathak, N. M., Gault, V. A., & Flatt, P. R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12508 · Cited by 17
Takagi, Y., Kinoshita, K., Ozaki, N., Seino, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138322 · Cited by 13
Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
Ahrén, B. (2015) · Diabetes · doi:10.2337/db14-1671 · Cited by 13
“glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.”
BackgroundResultAndo, H., Gotoh, K., Fujiwara, K., Anai, M., Chiba, S., Masaki, T., Kakuma, T., & Shibata, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-05371-4 · Cited by 14
Blockade of glucagon receptor induces α-cell hypersecretion by hyperaminoacidemia in mice
Jia, J., Bai, X., Kang, Q., Jiang, F., Wong, F. S., Jin, Q., & Li, M. (2025) · Nature Communications · doi:10.1038/s41467-025-57786-7 · Cited by 16
Fan, S., Dakshinamoorthy, J., Kim, E. R., Xu, Y., Huang, C., & Tong, Q. (2016) · Scientific Reports · doi:10.1038/srep19980 · Cited by 13
Glucagon regulates orexin A secretion in humans and rodents
Arafat, A. M., Kaczmarek, P., Skrzypski, M., Pruszyńska‐Oszmałek, E., Kolodziejski, P. A., Adamidou, A., Ruhla, S., Szczepankiewicz, D., Sassek, M., Billert, M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3335-4 · Cited by 14
“Insulinopenic diabetes was induced according to published protocols [31, 34].”
MethodSmall molecule glucagon receptor antagonists: a patent review (2011 – 2014)
Filipski, K. J. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1032250 · Cited by 12
“Evidence for glycemic efficacy with this mechanism also comes from GCGR knockout mice [7-11], glucagon antibodies [12,13], and GCGR-antisense therapy [14,15].”
BackgroundAn optical method to evaluate both mass and functional competence of pancreatic α- and β-cells
Wang, Y., Han, C., Zhu, W., Wu, Z., Liu, Y., & Chen, L. (2016) · Journal of Cell Science · doi:10.1242/jcs.184523 · Cited by 12
“Conversely, the elimination of β-cell mass in glucagon-receptornull mice does not cause diabetes (Lee et al., 2011; Sorensen et al., 2006; Yang et al., 2011).”
BackgroundHow does leptin restore euglycemia in insulin-deficient diabetes?
Oberlin, D. J., & Buettner, C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91880 · Cited by 13
Kang, Q., Hu, M., Jia, J., Bai, X., Liu, C., Wu, Z., Chen, W., & Li, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030724 · Cited by 12
“Additionally, the gcgr−/− mice are resistant to develop hyperglycemia in STZ-induced T1D and high-fat diet induced T2D models [7,8].”
BackgroundPreproglucagon Products and Their Respective Roles Regulating Insulin Secretion
Bethea, M. M., Bozadjieva-Kramer, N., & Sandoval, D. A. (2021) · Endocrinology · doi:10.1210/endocr/bqab150 · Cited by 12
Glucagon receptor blockage inhibits β-cell dedifferentiation through FoxO1
Wang, K., Cui, X., Li, F., Li, X., Wei, T., Liu, J., Fu, W., Yang, J., Hong, T., & Wei, R. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2022 · Cited by 12
Lang, V., Youssef, N., & Light, P. E. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0233-8 · Cited by 11
Vijayakumar, V., Mavathur, R. N., Raguram, N., Ranjani, H., Anjana, R. M., & Mohan, V. (2021) · Journal of Diabetology · doi:10.4103/jod.jod_6_18 · Cited by 13
Hepatic sialic acid synthesis modulates glucose homeostasis in both liver and skeletal muscle
Peng, J., Yu, L., Huang, L., Paschoal, V. A., Chu, H., de Souza, C. O., Varre, J. V., Oh, D. Y., Kohler, J. J., Xiao, X., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101812 · Cited by 12
Leptin for type 1 diabetes: coming onto stage to be (or not?)
Oral, E. A. (2012) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00797.x · Cited by 10
“More recently, the same laboratory has published that glucagon receptor-deficient mice treated with streptozotocin (STZ) did not develop a need for insulin therapy despite losing insulin secretion (11).”
BackgroundDamiano, F., Mercuri, E., Stanca, E., Gnoni, G. V., & Siculella, L. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.07.011 · Cited by 10
Glucagon infusion alters the hyperpolarized 13C‐urea renal hemodynamic signature
Qi, H., Mariager, C. Ø., Nielsen, P. M., Schroeder, M., Lindhardt, J. L., Nørregaard, R., Klein, J. D., Sands, J. M., & Laustsen, C. (2018) · NMR in Biomedicine · doi:10.1002/nbm.4028 · Cited by 10
Singha, A. K., Palavicini, J. P., Pan, M., Farmer, S., Sandoval, D. A., Han, X., & Fujikawa, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.588447 · Cited by 10
Li, H., Liu, T., Lim, J., Gounko, N. V., Hong, W., & Han, W. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.001 · Cited by 10
Protein kinase C-δ signaling regulates glucagon secretion from pancreatic islets
Yamamoto, K., Mizuguchi, H., Tokashiki, N., Kobayashi, M., Tamaki, M., Sato, Y., Fukui, H., & Yamauchi, A. (2017) · The Journal of Medical Investigation · doi:10.2152/jmi.64.122 · Cited by 10
Glucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
“[83 && ] reported that in three T1DM rat models of poorly controlled diabetes, the antidiabetic effects of leptin are not necessarily associated with suppression of glucagon production and/or action [2,4].”
BackgroundGlucagon-producing cells are increased in Mas-deficient mice
Braga, J. F., Dartora, D. R., Alenina, N. V., Bäder, M., & Santos, R. A. S. (2016) · Endocrine Connections · doi:10.1530/ec-16-0098 · Cited by 9
Changes in insulin, glucagon and ER stress precede immune activation in type 1 diabetes
Crookshank, J. A., Serrano, D., Wang, G., Patrick, C., Morgan, B., Paré, M., & Scott, F. W. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0328 · Cited by 8
Long in the shade, glucagon re‐occupies centre court
Henquin, J. C., Accili, D., Åhrén, B., Boîtard, C., Seino, S., & Cerasi, E. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01476.x · Cited by 10
Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice
Lafferty, R. A., McShane, L. M., Franklin, Z. J., Flatt, P. R., O'Harte, F. P. M., & Irwin, N. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0106 · Cited by 8
Yang, M., Pan, M., Huang, D., Liu, J., Guo, Y., Liu, Y., Xiao, T., Mai, K., & Zhang, W. (2023) · Aquaculture · doi:10.1016/j.aquaculture.2023.740172 · Cited by 8
Sisnande, T., Brum, F. L., Matias, D. O., Ribeiro, F. D. S., Beninatto, T. M., Mohana‐Borges, R., de Magalhães, M. T. Q., & Lima, L. M. T. R. (2024) · Analytical Biochemistry · doi:10.1016/j.ab.2024.115570 · Cited by 7
GSM based Needleless Blood Glucose Monitoring System
Mohi ud din, Q. (2017) · Journal of Bioengineering and Biomedical Sciences · doi:10.4172/2155-9538.1000231 · Cited by 8
Glucagon delivery – An overview of current and future devices
Рабинович, А. Л., & Priefer, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.028 · Cited by 8
A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
Subramanian, V., Bagger, J. I., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.911616 · Cited by 10
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
Implication of Mitochondrial Cytoprotection in Human Islet Isolation and Transplantation
Wang, Y., Mendoza-Elias, J. E., Qi, M., Harvat, T. A., Ahn, S. J., Lee, D., Gutierrez, D., Jeon, H., Paushter, D. H., & Oberholzer, J. (2012) · Biochemistry Research International · doi:10.1155/2012/395974 · Cited by 12
“Recently, more and more evidence has demonstrated that chemical and/or ion communication among β-cells or between βcells and α-cells is important for the regulation of insulin secretion [123, 124].”
BackgroundAn AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon Production
Evans, M. R., Wei, S., Posner, B. A., Unger, R. H., & Roth, M. G. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115622201 · Cited by 8
Self-citationVemana, H. P., & Dukhande, V. V. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121935 · Cited by 7
ErbB3 is required for hyperaminoacidemia-induced pancreatic α cell hyperplasia
Kang, Q., Jia, J., Dean, E. D., Yuan, H., Dai, C., Li, Z., Jiang, F., Zhang, X.-K., Powers, A. C., Chen, W., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107499 · Cited by 7
ZBED3 exacerbates hyperglycemia by promoting hepatic gluconeogenesis through CREB signaling
Luo, Y., Ruan, C.-S., Zhao, F.-Z., Yang, M., Cui, W., Cheng, X., Luo, X.-H., Zhang, X.-X., & Zhang, C. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156049 · Cited by 8
He, S., Wang, D., Lu, Y., Chen, Y., Jin, X., Wang, C., Zhao, J., Ren, Y., Wang, L., Li, H., et al. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213477974 · Cited by 8
New avenues for the pharmacological management of type 2 diabetes: An update
Cuny, T., Guerci, B., & Cariou, B. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.09.002 · Cited by 7
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_9 · Cited by 10
Nuevas proyecciones fisiológicas, patológicas y terapéuticas de la leptina
Goldenberg, D., Santos, J. L., Hodgson, M. I., & Cortés, V. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000600008 · Cited by 17
Xu, Y., & Tong, Q. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.027 · Cited by 7
Qi, Y., Guo, X., & Guo, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_28 · Cited by 7
Advances in the clinical measurement of glucagon: from diagnosis to therapy
Kitamura, T., & Kobayashi, M. (2024) · Diabetology International · doi:10.1007/s13340-024-00704-x · Cited by 6
“Furthermore, the importance of glucagon in regulating blood glucose levels is further reinforced by the fact that blood glucose levels barely increase even when pancreatic β-cells are diminished by streptozotocin in pancreatic α-cell-deficient mice and glucagon receptor-deficient mice [3, 4].”
Protein Kinase C (Pkc)-δ Mediates Arginine-Induced Glucagon Secretion in Pancreatic α-Cells
Honzawa, N., Fujimoto, K., Kobayashi, M., Kohno, D., Kikuchi, O., Yokota‐Hashimoto, H., Wada, E., Ikeuchi, Y., Tabei, Y., Dorn, G. W., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074003 · Cited by 7
Kouketsu, T., Monma, R., Miyairi, Y., Sawatsubashi, S., Shima, H., Igarashi, K., Sugawara, A., & Yokoyama, A. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.133 · Cited by 5
Melander, S. A., Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16329 · Cited by 6
“Previous studies, with rodent models of T1D, have shown the importance of the glucagon receptor in regulating glucose homeostasis (Damond et al., 2016; Lee et al., 2011).”
ResultCombination Therapy with GABA and MgSO4 Improves Insulin Sensitivity in Type 2 Diabetic Rat
Sohrabipour, S., Sharifi, M. R., Sharifi, M., Talebi, A., & Soltani, N. (2022) · International Journal of Endocrinology · doi:10.1155/2022/2144615 · Cited by 7
“'e study has shown that, in diabetics, decrease in insulin is not as harmful as an increase in glucagon, as insulin deficient animals that were simultaneously knocked out of the glucagon receptor were normoglycemic [39].”
InfluentialImeglimin suppresses glucagon secretion and induces a loss of α cell identity
Tsuno, T., Li, J., Nishiyama, K., Kawasawa, Y. I., Inoue, R., Yajima, E. O., Nishiyama, A., Yabe, S. G., Kin, T., Okochi, H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102254 · Cited by 6
Bruner, K. R., Byington, I. R., Marx, T. J., Vasileva, A., Fletcher, T., Ghimire, S., Zappia, I. J., Shaju, Y., Zeng, J., Wachsmuth, H. R., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01899-w · Cited by 8
Suppression of islet homeostasis protein thwarts diabetes mellitus progression
Oh, S., Jorgensen, M. L., Wasserfall, C. H., Gjymishka, A., & Petersen, B. E. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.15 · Cited by 4
Hypothalamic glucagon signaling in fasting hypoglycemia
Pitchaimani, V., Arumugam, S., Thandavarayan, R. A., Karuppagounder, V., Afrin, M. R., Sreedhar, R., Harima, M., Suzuki, H., Miyashita, S., Suzuki, K., et al. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.04.006 · Cited by 4
Rôle du glucagon dans la physiopathologie et le traitement du diabète
Girard, J. R., & Gautier, J. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30207-3 · Cited by 4
da Silva, A. A., Hall, J. E., Dai, X., Wang, Z., Salgado, M. C., & do Carmo, J. M. (2021) · Diabetes · doi:10.2337/db21-0126 · Cited by 5
Type 1 diabetes: key drug targets and how they could influence future therapeutics
Kim, Y. K., Munir, K. M., & Davis, S. N. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2177150 · Cited by 5
“Although human studies have shown modest efficacy [60,64,66], concerns about adverse hepatic effects”
BackgroundA bright future for glucagon and alpha cell biology
Panzer, J. K., & Caicedo, A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0315 · Cited by 5
Osawa, S., Yasuda, T., Kaneto, H., Shimo, N., Yamamoto, Y., Kawamori, D., Miyatsuka, T., Matsuoka, T., & Shimomura, I. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12251 · Cited by 4
Glucagon’s Golden Jubilee at the University of Liège
Lefèbvre, P. J. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412469417 · Cited by 4
Endocrine regulation of the hepatic fasting response: cues, cooperation and consequences
Goldberg, D. T., & Goldstein, I. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01228-3 · Cited by 8
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_8 · Cited by 4
Himuro, M., Wakabayashi, Y., Taguchi, T., Katahira, T., Suzuki, L., Iida, H., Ogihara, T., Nishida, Y., Sasaki, S., Lynn, F. C., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06028-w · Cited by 3
Mikaélyan, N. P., Dvornikov, A. S., Mikaelyan, А. А., & Smirnova, N. V. (2019) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-019-04523-y · Cited by 3
MEYTS, P. D., & Lefèbvre, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00017-1 · Cited by 4
Role of Fibroblast Growth Factor 21 in Biology of Glucagon
Berglund, E. D., & Unger, R. H. (2013) · Diabetes · doi:10.2337/db12-1840 · Cited by 3
“More recently, it was reported that the metabolic abnormalities of diabetes cannot occur in glucagon receptor–null mice in which virtually all insulin-producing pancreatic b-cells are destroyed (5).”
BackgroundSelf-citationAn overview of glucagon research
Valverde, I. (2016) · Diabetologia · doi:10.1007/s00125-016-3946-z · Cited by 3
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_37 · Cited by 4
Molecular Pathology and Therapeutic Strategies of Type 2 Diabetes
Liao, H. Z., Liang, Y., Wang, Y., & Liang, C. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230320162753 · Cited by 4
Ghorani, E., Evans, M. L., & Simmons, D. S. (2016) · Practical Diabetes · doi:10.1002/pdi.2001 · Cited by 3
L’étrange histoire du glucagon
Schlienger, J.-L. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30183-3 · Cited by 2
Advances in basic research on glucagon and alpha cells
Hayashi, Y. (2024) · Diabetology International · doi:10.1007/s13340-024-00696-8 · Cited by 3
“…since gcgr −/− mice were resistant to developing diabetes after the destruction of islet beta cells by streptozotocin, glucagonocentric restructuring of diabetes was proposed by Unger, a pioneer in glucagon research who established the first glucagon radioimmunoassay, and colleagues [8–10].”
In Situ Microwave Fixation to Define the Terminal Rodent Brain MetabolomePreprint
Juras, J. A., Webb, M. B., Young, L. E. A., Markussen, K. H., Hawkinson, T. R., Buoncristiani, M. D., Bolton, K. E., Coburn, P. T., Williams, M. I., Sun, L. P. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.16.504166 · Cited by 2
Vastrad, B. M., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-7537007/v1 · Cited by 2
Immunoreactivity of cytotoxic T‐lymphocyte antigen 2 alpha in mouse pancreatic islet cells
Luziga, C. D. (2020) · Anatomia Histologia Embryologia · doi:10.1111/ahe.12541 · Cited by 2
Estes, S. K., Shiota, C., O’Brien, T. P., Printz, R. L., & Shiota, M. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00192.2023 · Cited by 1
Pixner, T., Chaikouskaya, T., Lauth, W., Zimmermann, G., Mörwald, K., Lischka, J., Furthner, D., Awender, E., Geiersberger, S., Maruszczak, K., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1368570 · Cited by 3
Lee, J., Ustione, A., Wilkerson, E., Balakrishnan, R., Thurmond, D. C., Goldfarb, D., & Piston, D. W. (2025) · Diabetes · doi:10.2337/db24-1003 · Cited by 5
Role of glucagon in treating diabetes: Evidence and concepts (胰高血糖素在糖尿病治疗中的作用:证据与概念)
Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12107 · Cited by 1
Eliasson, L., & Wendt, A. (2016) · eLife · doi:10.7554/elife.16798 · Cited by 1
Insulin and the cellular death
Макишева, & Макишева, Р. Т. (2015) · Journal of New Medical Technologies · doi:10.12737/10812 · Cited by 1
Nakamura, Y., Horie, I., Tashiro, S., Kobayashi, M., Kitamura, T., Kusunoki, Y., Nishida, K., Yamamoto, A., Hirota, Y., Fukui, T., et al. (2021) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000135 · Cited by 2
Yu, X., Wen, X., Xu, J., Zhou, Q., Chen, Y., Qu, F., He, M., Chang, H., & Zheng, C. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01962 · Cited by 2
Kontola, H., Crisóstomo, L., Löyttyniemi, E., Koskenniemi, J. J., Veijola, R., Toppari, J., & Kero, J. T. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf601
Hashimoto, K.-I., Horikawa, Y., & Takeda, J. (2015) · Diabetology International · doi:10.1007/s13340-015-0219-x · Cited by 1
“However, a recent study in glucagon receptor knockout mice has shown that diabetes-associated hyperglycemia, the depletion of glycogen, an increase in gluconeogenesis, and an increase in ketone bodies all are found only in the presence of the actions of glucagon [18].”
BackgroundGlucagón: ¿un simple espectador o un jugador clave en la fisiopatología de la diabetes?
Lima-Martínez, M. M., Betancourt, L. R., & Bermúdez, A. (2011) · Avances en Diabetología · doi:10.1016/j.avdiab.2011.09.002 · Cited by 6
Piro, S., Urbano, F., Folli, F. B., Finzi, G., Marselli, L., & Marchetti, P. (2016) · Endocrinology · doi:10.1007/978-3-319-27318-1_31-1 · Cited by 1
Geary, N. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00150-0 · Cited by 2
Mikaélyan, N. P., Гурина, А. Е., Смирнов, В. В., Mikaelyan, A. V., & Terentyev, A. A. (2016) · Russian Medicine · doi:10.18821/0869-2106-2016-22-4-189-193 · Cited by 1
The entero-insular axis: a journey in the physiopathology of diabetes
Malaguarnera, R., Scamporrino, A., Filippello, A., Mauro, S. D., Minardo, A., Purrello, F., & Piro, S. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00025 · Cited by 2
“Lee Y, Berglund ED, Wang MY, Fu X, Yu X, Charron MJ, et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action.”
BackgroundResultInfluentialWang, J., Osada, T., Morse, M. A., Calzone, F. J., Yan, H., Thai, D. L., & Lyerly, H. K. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1881504 · Cited by 1
Piro, S., Urbano, F., Folli, F. B., Finzi, G., Marselli, L., & Marchetti, P. (2018) · Endocrinology · doi:10.1007/978-3-319-44675-2_31 · Cited by 1
Qi, Y., Guo, X., & Guo, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_28-1 · Cited by 1
Pham, R. N., & Do, T. M. N. (2011) · Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver
Glucagon, physiologie et physiopathologie
Mouly, C. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.11.012
Prolactin as an Adjunct to Anti-CD3 Type I Diabetes Therapy
Hyslop, C. M. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27455
Metadata
- Authors
- Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Albert Einstein College of Medicine (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Unger, Roger H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 391-397
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028337
- OpenAlex
- W1986861420
- Cited by
- 327
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 40 · 2014: 25 · 2013: 23 · 2012: 26
- FWCI
- 32.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK081194, DK081194)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon receptor, type 1 diabetes, insulin deficiency, beta cell destruction, streptozotocin, alpha cell hyperplasia, hyperglucagonemia, phosphoenolpyruvate carboxykinase, ketogenesis, hyperketonemia, glucose tolerance, free fatty acids, beta-hydroxybutyrate
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Glucagon, Hyperglycemia, Immunohistochemistry, Insulin, Insulin-Like Growth Factor I, Liver, Pancreas, Radioimmunoassay, Blotting, Western, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.